News
VTYX
14.00
0.00%
0.00
Eli Lilly Expands Into Sleep Medicine With Centessa Buyout
Benzinga · 03/31 14:48
Assessing Ventyx Biosciences (VTYX) Valuation After A Sharp 90 Day Share Price Rebound
Simply Wall St · 03/06 22:26
*News On Ventyx Biosciences Inc. (VTYX) Now Under LLY
Dow Jones · 03/04 22:08
Ventyx Biosciences Completes Cash Merger and Equity Payout
TipRanks · 03/04 14:49
Ventyx Biosciences Shareholders Approve Merger With Eli Lilly
TipRanks · 03/04 01:09
NASDAQ TRADE HALT <VTYX.O> TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Reuters · 03/04 00:50
Ventyx Biosciences Inc. Held Special Stockholder Meeting
Reuters · 03/03 22:08
Weekly Report: what happened at VTYX last week (0223-0227)?
Weekly Report · 03/02 09:39
BioAge Labs initiated with an Outperform at Oppenheimer
TipRanks · 02/24 21:48
Ventyx Faces Eli Lilly Acquisition, Delisting and Litigation
TipRanks · 02/23 22:08
Ventyx Faces New York Shareholder Lawsuits Over Merger Proxy Disclosures
Reuters · 02/23 21:27
Weekly Report: what happened at VTYX last week (0216-0220)?
Weekly Report · 02/23 09:38
Weekly Report: what happened at VTYX last week (0209-0213)?
Weekly Report · 02/16 09:38
Ventyx Biosciences subsidiary gets orphan designation for pericarditis treatment
TipRanks · 02/13 20:05
Eli Lilly Is Partnering with Gene-Editing Start-up Seamless Therapeutics. Here's What Investors Need to Know.
The Motley Fool · 02/10 14:35
Weekly Report: what happened at VTYX last week (0202-0206)?
Weekly Report · 02/09 09:39
Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX
Barchart · 02/05 16:21
Largest borrow rate increases among liquid names
TipRanks · 02/04 13:45
Ventyx Biosciences Sets March 3, 2026 Vote on Eli Lilly $14-Per-Share Cash Merger
TipRanks · 02/02 21:45
Weekly Report: what happened at VTYX last week (0126-0130)?
Weekly Report · 02/02 09:38
More
Webull provides a variety of real-time VTYX stock news. You can receive the latest news about Ventyx Biosciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About VTYX
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its lead portfolio of NOD-like receptor protein 3 (NLRP3) inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase II development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase II development for neurodegenerative and cardiometabolic diseases. Its inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase II clinical trials. Tamuzimod is a sphingosine 1 phosphate receptor (S1P1R) modulator in development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is a selective allosteric tyrosine kinase type 2 (TYK2) inhibitor in Phase II development for the treatment of moderately to severely active Crohn’s disease.